FOLD
AMICUS THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$14.49
+0.00%Latest reported
- Last report date
- Feb 20, 2026
- EPS actual
- $0.10
- EPS estimate
- $0.13
- Revenue actual
- $185.2M
- Revenue estimate
- $185.0M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -23.5%
- Revenue beats (12Q)
- 3
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Feb 20, 2026 | $0.13 | $0.10 | Miss -23.08% | $185.2M |
| Nov 4, 2025 | $0.12 | $0.17 | Beat 41.67% | $169.1M |
| Jul 31, 2025 | $0.02 | $0.01 | Miss -50.00% | $154.7M |
| May 1, 2025 | $0.08 | $0.03 | Miss -62.50% | $125.2M |
| Feb 19, 2025 | $0.02 | $0.09 | Beat 350.00% | $149.7M |
| Aug 8, 2024 | $0.05 | $0.06 | Beat 9.83% | $126.7M |
| May 9, 2024 | -$0.06 | -$0.02 | Beat 66.67% | $110.4M |
| Feb 28, 2024 | -$0.06 | -$0.11 | Miss -83.33% | $115.1M |
| Nov 8, 2023 | -$0.08 | -$0.07 | Beat 12.50% | $103.5M |
| Mar 1, 2023 | -$0.13 | -$0.19 | Miss -46.15% | $88.1M |
| Aug 4, 2022 | -$0.23 | -$0.21 | Beat 8.70% | $80.7M |
| Feb 24, 2022 | -$0.14 | -$0.29 | Miss -107.14% | $82.2M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of May 7, 2026